Research Analysts Offer Predictions for AGIO Q1 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – HC Wainwright lifted their Q1 2026 EPS estimates for shares of Agios Pharmaceuticals in a report issued on Thursday, February 12th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings of ($1.82) per share for the quarter, up from their prior estimate of ($1.86). HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q2 2026 earnings at ($1.66) EPS, Q3 2026 earnings at ($1.63) EPS, Q4 2026 earnings at ($1.58) EPS, FY2026 earnings at ($6.68) EPS, FY2027 earnings at ($5.48) EPS, FY2028 earnings at ($4.24) EPS and FY2029 earnings at ($2.49) EPS.

AGIO has been the subject of a number of other research reports. Zacks Research upgraded Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Bank of America increased their price target on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Finally, The Goldman Sachs Group lowered their price target on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, November 20th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $39.78.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $27.96 on Monday. The company has a 50-day simple moving average of $27.41 and a two-hundred day simple moving average of $33.95. The firm has a market capitalization of $1.64 billion, a PE ratio of -3.93 and a beta of 0.91. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $3,314,000. Panagora Asset Management Inc. purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth approximately $2,173,000. Kennedy Capital Management LLC grew its position in Agios Pharmaceuticals by 166.4% in the 4th quarter. Kennedy Capital Management LLC now owns 65,655 shares of the biopharmaceutical company’s stock worth $1,787,000 after purchasing an additional 41,014 shares during the period. Entropy Technologies LP bought a new stake in Agios Pharmaceuticals in the 4th quarter worth approximately $522,000. Finally, Aigen Investment Management LP purchased a new stake in Agios Pharmaceuticals during the 4th quarter valued at $705,000.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,932 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the sale, the insider owned 29,190 shares in the company, valued at $790,757.10. This represents a 9.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Brian Goff sold 18,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $506,664.27. Following the completion of the transaction, the chief executive officer owned 136,583 shares of the company’s stock, valued at approximately $3,700,033.47. The trade was a 12.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 33,303 shares of company stock valued at $901,977. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.